Sugi Predict

Sugi Predict / Compounds / SCHEMBL23043319

SCHEMBL23043319

SCHEMBL23043319

CC1(C)OB(c2cccc3ccc(F)cc23)OC1(C)C

nearest known ligand 0.42

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ LPL P06858 5/20 0.42
▸ LIPG Q9Y5X9 5/20 0.42
▸ JAK2 O60674 3/20 0.36
▸ BTK Q06187 3/20 0.36
▸ CYP1A2 P05177 3/20 0.36
▸ CYP2A6 P11509 1/20 0.36
▸ IDO1 P14902 2/20 0.36
▸ TDO2 P48775 1/20 0.35
▸ ACHE P22303 1/20 0.33
▸ IRAK4 Q9NWZ3 1/20 0.32
▸ CXCR2 P25025 3/20 0.32
▸ CYP1A1 P04798 2/20 0.30
▸ CYP1B1 Q16678 2/20 0.30
▸ CYP19A1 P11511 1/20 0.30
▸ PRKDC P78527 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30876507 1.00 LPL (0.42) LPLLIPGJAK2BTKCYP1A2
SCHEMBL29634815 1.00 LPL (0.42) LPLLIPGJAK2BTKCYP1A2
SCHEMBL30065387 0.88 LPL (0.42) LPLLIPGJAK2BTKCYP1A2
SCHEMBL22555255 0.88 LPL (0.42) LPLLIPGJAK2BTKCYP1A2
SCHEMBL30640509 0.83 CYP2A6 (0.49) LPLLIPGJAK2BTKCYP1A2
SCHEMBL30369989 0.83 JAK2 (0.39) LPLLIPGJAK2BTKIRAK4
SCHEMBL1643598 0.83 LIPG (0.53) LPLLIPGIDO1TDO2IRAK4
SCHEMBL23043783 0.83 CYP2A6 (0.49) LPLLIPGJAK2BTKCYP1A2
SCHEMBL25177449 0.83 JAK2 (0.39) LPLLIPGJAK2BTKIRAK4
SCHEMBL31685154 0.81 LPL (0.35) LPLLIPGJAK2BTKIDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630566-B2 KRas G12D inhibitors Mirati Therapeutics, Inc. (US) 2026-05-19 — — US disclosed
US-12600717-B2 Tricyclic compounds as inhibitors of KRAS INCYTE CORPORATION (US) 2026-04-14 — — US disclosed
US-20250368641-A1 QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS INCYTE CORP (US) 2025-12-04 — — US disclosed
US-12378243-B2 Quinoline compounds as inhibitors of KRAS INCYTE CORPORATION (US) 2025-08-05 — — US disclosed
US-20250188073-A1 TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS INCYTE CORP (US) 2025-06-12 — — US disclosed
EP-4548918-A2 TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS Incyte Corporation (US) 2025-05-07 — — EP disclosed
EP-4536668-A1 PYRIDO[4,3-D]PYRIMIDINE DERIVATIVES AS KRAS INHIBITORS Bristol-Myers Squibb Company (US) 2025-04-16 — — EP disclosed
US-20240368152-A1 QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS INCYTE CORPORATION 2024-11-07 — — US disclosed
US-20240309020-A1 KRAS G12D INHIBITORS ARRAY BIOPHARMA INC. 2024-09-19 — — US disclosed
EP-4415824-A1 QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS Incyte Corporation (US) 2024-08-21 — — EP disclosed
WO-2023287896-A1 TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS INCYTE CORPORATION (US) 2023-01-19 — — WO disclosed
US-11453683-B1 KRas G12D inhibitors Mirati Therapeutics, Inc. (US) 2022-09-27 — — US disclosed
EP-4021444-A1 KRAS G12D INHIBITORS Mirati Therapeutics, Inc. (US) 2022-07-06 — — EP disclosed
CN-114615981-A KRAS G12D inhibitors 米拉蒂治疗股份有限公司 2022-06-10 — — CN disclosed
WO-2022098625-A1 KRAS G12D INHIBITORS Mirati Therapeutics, Inc. (US) 2022-05-12 — — WO disclosed
WO-2022015375-A1 KRAS G12D INHIBITORS Mirati Therapeutics, Inc. (US) 2022-01-20 — — WO disclosed
US-20210355121-A1 FUSED TRICYCLIC KRAS INHIBITORS INCYTE CORPORATION 2021-11-18 — — US disclosed
WO-2021211864-A1 FUSED TRICYCLIC KRAS INHIBITORS INCYTE CORPORATION (US) 2021-10-21 — — WO disclosed
WO-2021041671-A1 KRAS G12D INHIBITORS Mirati Therapeutics, Inc. (US) 2021-03-04 — — WO disclosed
WO-2021041671-A1 KRAS G12D INHIBITORS Mirati Therapeutics, Inc. (US) 2021-03-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12600717-B2 Tricyclic compounds as inhibitors of KRAS KRAS, NRAS, HRAS LPL 4192/4885LIPG 4098/4885JAK2 409/4885
US-12378243-B2 Quinoline compounds as inhibitors of KRAS KRAS, NRAS, HRAS LPL 4454/4885LIPG 3005/4885JAK2 1133/4885
US-20240368152-A1 QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS KRAS, NRAS, HRAS LPL 4454/4885LIPG 3005/4885JAK2 1133/4885
US-12630566-B2 KRas G12D inhibitors KRAS, NRAS, HRAS LPL 3982/4885LIPG 2426/4885JAK2 435/4885
US-20250188073-A1 TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS KRAS, NRAS, HRAS LPL 4234/4885LIPG 2510/4885JAK2 1457/4885
US-20250368641-A1 QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS KRAS, NRAS, HRAS LPL 4454/4885LIPG 3005/4885JAK2 1133/4885
US-20210355121-A1 FUSED TRICYCLIC KRAS INHIBITORS KRAS, NRAS, HRAS LPL 3977/4885LIPG 2804/4885JAK2 1427/4885
US-11453683-B1 KRas G12D inhibitors KRAS, NRAS, HRAS LPL 3911/4885LIPG 3165/4885JAK2 414/4885
US-20240309020-A1 KRAS G12D INHIBITORS KRAS, NRAS, HRAS LPL 4181/4885LIPG 3541/4885JAK2 1126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.